| Main Products |
 |
| Gastrointestinal Field |
 |
|
 |
Acinon® Tablets 150mg,
a histamine H2 receptor antagonist |
Promac® D Tablets 75,
a zinc containing anti-ulcerant |
 |
|
 |
Asacol® Tablets 400mg,
an ulcerative colitis remedy |
Visiclear® Combination Tablets,
an oral bowel cleansing agent for colonoscopy |
|
|
| Others |
 |
|
 |
Landel® Tablets 40,
a long-acting calcium channel blocker |
Peon® Tablets 80,
an oral non-steroidal anti-inflammatory |
 |
|
 |
Ancer® S.C. Injection 20µg,
an anti-leukopenia after radiotherapy |
Avitene® Flour Type,
an absorbable topical hemostat
|
|
|
| A Proven Track Record as a Specialty Pharma |
|
|
In Ethical Pharmaceuticals, we are enhancing our new drug pipeline through developing our own original drugs and forging strategic alliances together with focusing on life cycle management that includes adding new pharmaceutical forms and indications to existing drugs.
A particularly important therapeutic area is the gastrointestinal field. Many of our products have earned high acclaim, including Acinon® Tablets 75mg and 150mg, a histamine H2 receptor antagonist, gastric/duodenal anti-ulcerant and reflux esophagitis agent; Promac® Granules 15% and D Tablets 75, a zinc-containing anti-ulcerant; Marzulene® S Combination Granules, Tablets 0.5/1.0ES, an anti-inflammatory anti-ulcerant; New Lecicarbon® Suppositories, a laxative; and Visiclear® Combination Tablets, an oral bowel cleansing agent for colonoscopy. In 2009, with the addition of Asacol® Tablets 400mg, an ulcerative colitis remedy, we offer a full lineup of gastrointestinal drugs as we strive to firmly establish a position as "Zeria, your gastrointestinal specialist."
In other fields as well, we are supplying excellent products that meet the latest medical needs, including Landel® Tablets 10, 20 and 40 for hypertension and angina pectoris; Peon® Tablets 80, an oral non-steroidal anti-inflammatory drug; Ancer® S.C. Injection 20µg, an anti-leukopenia after radiotherapy; and Avitene® and Syringe Avitene®, an absorbable topical hemostat.
|
| Highly Detailed MR Activities Support Leading-Edge Medical Fields |
|
|
To ensure that our pharmaceuticals are always used correctly, it is essential to promptly and appropriately provide information to medical professionals, mainly physicians and pharmacists. This crucial role is entrusted to our medical representatives (MRs).
Zeria has assigned MRs throughout Japan. While maintaining close cooperation with specialized medical product wholesalers (specified distributors), these MRs carry out ethical pharmaceutical support activities.
Our MRs also provide up-to-date information on findings, characteristics and proper usage of our products, mainly to medical professionals at university hospitals and major hospitals as well as general practitioners. Zeria was a frontrunner in promoting the introduction of information technology (IT) for handling pharmaceutical data. To this end, we built the proprietary Ark System for the real-time provision and collection of information and knowledge sharing. At the same time, we are enhancing efficiency and convenience via Internet-based e-promotions. On our "Gastrointestinal Online Site," a useful online portal for medical professionals, we provide information on the efficacy and safety of our main products and on the diagnosis and treatment of gastrointestinal diseases.
In collaboration with medical professionals, we also host workshops, symposiums and seminars, while actively providing journals and other literature. |
 |
|
 |
| Further Expanding Markets by Increasing and Expanding Sales Capabilities
for Gastrointestinal Therapies |
|
|
In the current fiscal year, by clearly differentiating our product portfolio, Zeria will work to achieve deeper market penetration for such existing pharmaceuticals as Acinon®, Promac® and Visiclear®. Concurrently, we will actively undertake sales activities to swiftly achieve market penetration for Asacol®, an ulcerative colitis remedy, scheduled for launch in December 2009.
We will emphasize the unique features of Acinon®, such as its gastroprokinetic effect and salivary secretion effect not possessed by other H2 blockers. We will also promote Promac® as a high value-added, anti-ulcer drug that can be prescribed for treating factitious ulcers following endoscopic submucosal dissection (ESD). Zeria will carry out comprehensive sales activities for Visiclear®, the first oral bowel cleansing agent in tablet form in Japan, emphasizing the ease of taking this drug and its outstanding cleansing effects, in order to expand its usage.
We will market Asacol® as a single brand through two channels in accordance with a co-development and co-marketing agreement with Kyowa Hakko Kirin Co., Ltd. (formerly, Kyowa Hakko Kogyo Co., Ltd.). Along with these efforts, as a new initiative we established the Gut Challenge Meeting (GCM), which is a participatory-type, discussion-based meeting on diagnosis and treatment targeted at young physicians throughout Japan specializing in lower gastrointestinal tract diseases.
With the launch of Asacol®, we will complete our full lineup of gastrointestinal drugs covering the upper and lower gastrointestinal tracts. In this fiscal year, we will continue to provide high-quality information on efficacy and safety centered on Promac®, Acinon®, Visiclear® and Asacol®, as we vigorously work to establish a position as "Zeria, your gastrointestinal specialist." |
 |
| Acinon® Tablets 75mg and 150mg
|
|
 |
| Promac® Granules 15%
|
|
Promac® D Tablets 75 |
|
|
 |
| Asacol® Tablets 400mg |
|
 |
Pamphlet
introducing GCM |
|
 |
| GCM sessions
|
|
|